In focus · trending topic

orphandisease

52 stories · following the connections

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC